Clinical Trials for Pulmonary Fibrosis in the Era of Effective Therapies

The necessity of clinical trials for pulmonary fibrosis in an era where there are effective therapies and the challenges the trials face in order to be successful are both discussed in this Pulmonary Fibrosis Foundation video. Dr. Luca Richeldi, MD, PhD. suggested that there are three issues that need to be addressed for clinical trials to be relevant, which are the mechanisms to target, which patients to enroll and the endpoint that is to be measured.

Preclinical data support start of clinical studies of potential treatment for IPF. Read more here. 

Dr. Richeldi presented the session at the PFF Summit 2015: From Bench to Bedside in November 2015 in Washington D.C. where he explains the ongoing importance of pulmonary fibrosis patients participating in clinical trials to help further research, discover better treatments and medications and ultimately come up with a cure for the disease.

Discover some of the most frequently asked questions about clinical trials here.

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.